Passage Bio
Biotechnology ResearchPennsylvania, United States51-200 Employees
We are a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Our lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. Our team's unwavering commitment to excellence is the driving force behind our mission to protect patients and their families against loss in neurodegenerative conditions.
1-888-653-2347 
support@leadiq.com 
